Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr;58(2):107-19.
doi: 10.1007/s00005-010-0063-4. Epub 2010 Feb 9.

Lentiviral vectors in gene therapy: their current status and future potential

Affiliations
Review

Lentiviral vectors in gene therapy: their current status and future potential

David Escors et al. Arch Immunol Ther Exp (Warsz). 2010 Apr.

Abstract

The concept of gene therapy originated in the mid twentieth century and was perceived as a revolutionary technology with the promise to cure almost any disease of which the molecular basis was understood. Since then, several gene vectors have been developed and the feasibility of gene therapy has been shown in many animal models of human disease. However, clinical efficacy could not be demonstrated until the beginning of the new century in a small-scale clinical trial curing an otherwise fatal immunodeficiency disorder in children. This first success, achieved after retroviral therapy, was later overshadowed by the occurrence of vector-related leukemia in a significant number of the treated children, demonstrating that the future success of gene therapy depends on our understanding of vector biology. This has led to the development of later-generation vectors with improved efficiency, specificity, and safety. Amongst these are HIV-1 lentivirus-based vectors (lentivectors), which are being increasingly used in basic and applied research. Human gene therapy clinical trials are currently underway using lentivectors in a wide range of human diseases. The intention of this review is to describe the main scientific steps leading to the engineering of HIV-1 lentiviral vectors and place them in the context of current human gene therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Basic engineering of lentivectors. The self-inactivating (SIN) lentiviral transfer vector (a) and the resulting lentivector (b). The SIN vector contains a modified U3 region within the 3′ LTR, in which the enhancer/promoter sequences have been deleted as shown in the transfer vector. Abbreviations: CA, capsid; CTS, central termination site; IN, integrase; LTR, long terminal repeat; MA, matrix; NC, nucleocapsid; PPT, polypurine tract; PR, protease; RT, reverse transcriptase; SU, surface; TM, transmembrane; TRIP: triple helix; WPRE: woodchuck hepatitis B posttranscriptional element.
Figure 2
Figure 2
Characteristics of lentiviruses and development of improved recombinant lentivectors.

Similar articles

Cited by

References

    1. Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, Takahashi T, Ikawa M, Okabe M, Inoue N, Okamoto-Tanaka M, Ishizaki H, Miyoshi J, Matsumoto M, Seya T. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A. 2007a;104:252–7. - PMC - PubMed
    1. Akazawa T, Shingai M, Sasai M, Ebihara T, Inoue N, Matsumoto M, Seya T. Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. FEBS Lett. 2007b;581:3334–40. - PubMed
    1. Anderson WF, Blaese RM, Culver K. The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. Hum Gene Ther. 1990;1:331–62. - PubMed
    1. Andreadis ST, Brott D, Fuller AO, Palsson BO. Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5.5 to 7.5 hours. J Virol. 1997;71:7541–8. - PMC - PubMed
    1. Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP, Thrasher AJ, Collins MK, Philpott NJ. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther. 2007;15:1947–54. - PubMed